Early publication of Essity's Interim Report for quarter 1, 2022
STOCKHOLM, April 21, 2022 /PRNewswire/ -- Essity's Interim Report for quarter 1, 2022 will be published on Friday, April 22, 2022, at approximately 07:00 CET instead of Thursday, April 28, 2022 as previously communicated. In conjunction with publication, a telephone and web presentation will be held at 09:00 CET where President and CEO Magnus Groth will present and answer questions.
Telephone: +44 333 300 08 04 or +1 631 913 14 22 or +46 8 566 426 51. Please call in well in advance of the start of the presentation. State pin code: 70624732#
The presentation of the Interim Report will also be available on LinkedIn and Twitter
For further information, please contact: Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55, [email protected] Johan Karlsson, Vice President Investor Relations, +46 705 11 15 81, [email protected]
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
